Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer

AKÇA H., DEMİRAY A., YAREN A., Bir F., KÖSELER A., Iwakawa R., ...Daha Fazla

CANCER GENETICS, cilt.206, sa.3, ss.73-80, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 206 Sayı: 3
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1016/j.cancergen.2013.01.005
  • Dergi Adı: CANCER GENETICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.73-80
  • Anahtar Kelimeler: EGFR, mutations, NSCLC, Turkish, serum DNA, FACTOR RECEPTOR MUTATIONS, K-RAS MUTATIONS, CIRCULATING DNA, GENE-MUTATIONS, PLASMA DNA, GEFITINIB, TUMOR, CARCINOMA, THERAPY, CHEMOTHERAPY
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Mutations in the EGFR gene are critical determinants of treatment with EGFR tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer (NSCLC) patients. DNA isolation from tumor samples usually requires surgery; therefore, we wanted to isolate DNA from circulating tumor cells by using the serum of NSCLC patients. This protocol was recently published. DNA was isolated from the serum of 52 Turkish NSCLC patients and their EGFR mutation status was examined by pyrosequencing. EGFR mutations were detected in 25 of the 52 patients (48.1%): 17 patients with delE746-A750, 2 with delE747-A750insP, and 6 with L858R. All mutations detected by pyrosequencing were confirmed by dideoxy sequencing, and the presence of the same mutations in the tumors was verified by using paraffin embedded tissues of all the patients. Mutations were detected more frequently in adenocarcinomas (24 of 36, 66.7%) than in squamous cell carcinomas (1 of 16, 6.3%) (P < 0.001). These results confirm the utility of serum DNA and pyrosequencing for the detection of EGFR mutations in patients with advanced NSCLC.